PMS-METOCLOPRAMIDE TABLETS 5 MG
METOCLOPRAMIDE HYDROCHLORIDE : 5 MG · DIN 02230431 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-METOCLOPRAMIDE TABLETS?
PMS-METOCLOPRAMIDE TABLETS 5 MG contains METOCLOPRAMIDE HYDROCHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02230431, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-METOCLOPRAMIDE TABLETS used for?
As an adjunct in the management of delayed gastric emptying associated with subacute and chronic gastritis or following vagotomy, pyloroplasty and other surgical procedures. As an adjunct to facilitate small bowel intubation and gastroduodenal evacuation of barium meals. To reduce postoperative vomiting induced by narcotics when used pre-operatively by the oral route.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02230431 |
|---|---|
| Brand name | PMS-METOCLOPRAMIDE TABLETS |
| Generic / active ingredient | METOCLOPRAMIDE HYDROCHLORIDE : 5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A03FA01 METOCLOPRAMIDE |
| AHFS class | 88:28.01* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Oct-2021 |
| Original market date | 1997-03-26 00:00:00 |
How is it administered?
Adults: 5-10 mg 3-4 times daily before meals. Max daily dose 0.5 mg/kg. Duration should not exceed 12 weeks. Reduced dose for elderly, renal/hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Tablets: HDPE bottles of 100 tablets (5 mg and 10 mg). Oral Solution: HDPE bottles of 500 mL.
Contraindications
Hypersensitivity; history of tardive dyskinesia or dystonic reaction; GI hemorrhage, obstruction, or perforation; pheochromocytoma; epilepsy; concomitant drugs causing extrapyramidal reactions.
Warnings and precautions
Tardive dyskinesia (often irreversible, risk increases with duration); Extrapyramidal symptoms; Neuroleptic Malignant Syndrome; Depression/suicidality; Hypertension; Fluid retention.
What can be used instead?
Other Canadian products sharing ATC code A03FA01 METOCLOPRAMIDE. 10 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-METOCLOPRAMIDE | 5 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02517795 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02537397 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02531747 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | Strength | Liquid | SANDOZ CANADA INCORPORATED 4600 Rue Armand-Frappier Saint-Hubert Quebec Canada J3Z 1G5 | MARKETED | DIN 02185431 |
| METOCLOPRAMIDE INJECTION USP | 5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02243563 |
| PMS-METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 5 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02510790 |
| PMS-METOCLOPRAMIDE ORAL SOLUTION | 5 MG / 5 ML | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02230433 |
| PRZ-METOCLOPRAMIDE | 10 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548755 |
| PRZ-METOCLOPRAMIDE | 5 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548747 |
| APO-METOCLOP TAB 10MG | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 00842834 |
Who else supplies METOCLOPRAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METOCLOPRAMIDE appears in 159 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.